Revelation Biosciences REVB 深 沪
等待开盘 07-14 09:30:00 美东时间
0.9869
-0.013
-1.31%
华盛通- 最 高1.02
- 今 开1.0198
- 成交量 1.89万股
- 最 低 0.9869
- 昨 收 1.00
- 总市值 385.72万
- 52周最高 12.88
- 市盈率 静 --
- 换手率 0.48%
- 52周最低 0.875
- 委 比 22.37%
- 总股本 390.84万
- 历史最高 2276064.00
- 量 比 0.40
- 振 幅 3.31%
- 历史最低 0.9869
- 每 手 1
- 风险率 3.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Revelation Biosciences Adopts Stockholder Rights Protection Plan
An update from Revelation Biosciences ( ($REVB) ) is now available. On July 10,...
今天 05:12
Revelation Biosciences' Board Implements Shareholder Rights Plan, Declares Dividend Distribution Of One Right For Each Outstanding Common Stock
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that its Board of Directors (the "Board") has adopted a stockholder rights plan (the "Rights Plan") a...
07-11 04:07
Revelation Biosciences Updates Executive Contracts, Shareholder Actions
Revelation Biosciences ( ($REVB) ) has shared an update. On June 24, 2026, Reve...
06-25 05:19
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_05082026_REVB_Sorensen.pdf
05-09 00:05
Revelation Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Revelation Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary Revelation Biosciences Inc REVB.OQ reported a quarterly adjusted loss of $2.71 per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-25.32. T
05-08 11:48
Revelation Biosciences Q1 EPS $(2.71) Misses $(1.55) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.71) per share which missed the analyst consensus estimate of $(1.55) by 74.84 percent. This is a 89.31 percent increase over losses of $(25.34) per
05-08 04:56
Revelation Biosciences Presents Additional Data Analysis From PRIME Study At International Conference On AKI & CRRT 2026
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence -SAN DIEGO, CA / ACCESS Newswire / March 30,
03-30 21:02
Revelation Biosciences says Gemini normalizes inflammation in PRIME study CKD patients
Revelation Biosciences says Gemini normalizes inflammation in PRIME study CKD patients Revelation Biosciences presented additional PRIME Study analyses at AKI & CRRT 2026 on March 29, 2026, highlighting Gemini effects in stage 3-4 chronic kidney disease patients. Data showed Gemini normalized cellul
03-30 21:02
Revelation Biosciences Shareholders Approve Warrant Share Issuance
Revelation Biosciences ( ($REVB) ) has shared an announcement. On March 18, 202...
03-20 04:51
Revelation Biosciences reports FY results
Revelation Biosciences press release (REVB): FY net loss of $59.76. As of December 31, 2025, Revelation had $10.7 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024...
02-27 20:02
